SUMOylation is an essential modification that regulates hundreds of proteins in eukaryotic cells. Owing to its dynamic nature and low steady-state levels, endogenous SUMOylation is challenging to detect. Here, we present a method that allows efficient enrichment and identification of endogenous targets of SUMO1 and the nearly identical SUMO2 and 3 (SUMO 2/3) from vertebrate cells and complex organ tissue. Using monoclonal antibodies for which we mapped the epitope, we enriched SUMOylated proteins by immunoprecipitation and peptide elution. We used this approach in combination with MS to identify SUMOylated proteins, which resulted in the first direct comparison of the endogenous SUMO1- and SUMO2/3-modified proteome in mammalian cells, to our knowledge. This protocol provides an affordable and feasible tool to investigate endogenous SUMOylation in primary cells, tissues and organs, and it will facilitate understanding of SUMO's role in physiology and disease.
SUMOylation is an essential modification that regulates hundreds of proteins in eukaryotic cells. Owing to its dynamic nature and low steady-state levels, endogenous SUMOylation is challenging to detect. Here, we present a method that allows efficient enrichment and identification of endogenous targets of SUMO1 and the nearly identical SUMO2 and 3 (SUMO 2/3) from vertebrate cells and complex organ tissue. Using monoclonal antibodies for which we mapped the epitope, we enriched SUMOylated proteins by immunoprecipitation and peptide elution. We used this approach in combination with MS to identify SUMOylated proteins, which resulted in the first direct comparison of the endogenous SUMO1- and SUMO2/3-modified proteome in mammalian cells, to our knowledge. This protocol provides an affordable and feasible tool to investigate endogenous SUMOylation in primary cells, tissues and organs, and it will facilitate understanding of SUMO's role in physiology and disease.
SUMOylation is an essential post-translational modification that regulates protein functions. All eukaryotes express at least one small ubiquitin-related modifier (SUMO) protein; higher eukaryotes including plants and vertebrates express several SUMO paralogs belonging to two subfamilies (SUMO1 and SUMO2/3) that have overlapping and distinct targets and functions. Mammalian SUMO1 shares 50% identity with SUMO2 and SUMO3, the latter of which are virtually identical. Hundreds of proteins are SUMOylated and deSUMOylated in a temporally and/or spatially controlled manner, such that selected targets may be SUMOylated only during a specific time in the cell cycle, in response to DNA damage or upon extracellular signals. Hence, SUMOylation contributes to numerous intracellular processes including transcription, DNA repair, chromatin remodeling and signal transduction (reviewed in refs. 1,2). Unsurprisingly, defects in SUMOylation have been associated with severe diseases such as cancer, neurodegeneration and heart failure (recent examples in refs. 3, 4) . Notably, numerous stress conditions are known to induce global changes in SUMOylation, both in tissue-cultured cells and at the organismic level. Examples for the latter are ischemia in the mouse brain 5 or hibernation torpor in ground squirrels 6, 7 . Studies in Arabidopsis thaliana suggest that these global changes are required for survival under adverse conditions 8 . Detailed understanding of SUMOylation, both at the level of individual target proteins and at the systemic level is, hence, essential for understanding of physiological and pathophysiological processes. However, there are two major problems with the detection of SUMO targets. First, many SUMOylated proteins such as transcription factors are low in abundance. Because only a small fraction of these targets are normally SUMOylated at steady state, detection by direct immunoblotting is often impossible. Second, SUMOylated species are rapidly lost upon cell lysis in nondenaturing buffers, owing to highly active SUMO isopeptidases. Consequently, large efforts have been made during recent years to develop protocols and tools for the identification and analysis of rare SUMOylated proteins. It is a common strategy to overexpress tagged versions of SUMO along with a putative target protein in cells and evaluate target modification by immunoblotting or immunoprecipitation followed by immunoblotting [9] [10] [11] [12] . To further boost SUMOylation, parts of the SUMOylation machinery (for example, the E2-conjugating enzyme Ubc9 or PIAS E3 ligases) can be coexpressed 9, [13] [14] [15] . Although these strategies are useful to test whether proteins can in principle be SUMOylated and can help in development of SUMOylation-deficient protein variants, they obviously provide little insight into the endogenous regulation of target SUMOylation and are limited to transfectable material and genetically modifiable organisms.
Tagged SUMO has also been used successfully to identify new SUMO targets on a global scale. Expression of histidine (His)-tagged SUMO followed by Ni pulldown [16] [17] [18] [19] allows denaturing cell lysis, which inhibits SUMO isopeptidases and breaks up noncovalent protein interactions. Expression of hemagglutinin-tagged SUMO allows immunoprecipitation with peptide elution, which is known to have little background [20] [21] [22] . Combinations of Ni pulldown and immunoprecipitation have been performed in many model organisms, such as Saccharomyces cerevisiae [23] [24] [25] [26] , Caenorhabditis elegans 27 , Drosophila melanogaster 28 and A. thaliana 29 , which resulted in the identification of hundreds of putative SUMO targets in the respective model organisms. In mammalian cells, a tandem affinity purification (TAP) of
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TAP-SUMO2-modified proteins has been very successful 30 . Of note, several of the screens mentioned above were performed under stress conditions 21, 22, 24, 29, 30 that are known to enhance SUMOylation 31 .
Analysis of endogenous SUMOylation, however, either at the level of individual targets or at a global scale, has only been possible in isolated cases. A recently developed protocol that allows global enrichment of SUMOylated proteins from untransfected cells makes use of the poly-SUMO-binding function of RNF4, a protein containing four SUMO-interacting motifs (SIMs). Although it has been successfully used to identify proteins modified by SUMO2/3 from HeLa cells upon heat stress 32 , it is limited to proteins that are poly-SUMOylated.
Although numerous protocols are available, analysis of individual SUMOylated proteins in untransfected cell lines, primary cells, complex organs and tissues including human patient material remains rather challenging. We therefore developed a protocol that allows high enrichment of endogenously SUMOylated proteins from a wide range of vertebrate cells and tissues. It involves monoclonal antibodies to SUMO1 and SUMO2/3 that are readily available and is hence affordable and widely applicable both for the analysis of individual SUMOylated proteins and for global analysis of the SUMOylated proteome . As a proof of principle, we provide the first direct comparison, to our knowledge, of the SUMO1-and SUMO2/3-target proteomes in HeLa cells and demonstrate that endogenous SUMO targets can be efficiently enriched and identified from mouse liver. With this protocol, investigating the role of endogenous SUMOylation to answer physiological and disease-related questions will become feasible.
RESULTS

Enrichment of SUMOylated proteins with monoclonal antibodies
To isolate endogenous SUMOylated species, we turned to two well-known monoclonal anti-SUMO1 and anti-SUMO2/3 antibodies (SUMO1 21C7 and SUMO2 8A2), whose hybridoma cells were developed previously 33, 34 and can be obtained from the Developmental Studies Hybridoma Bank at the University of Iowa, Iowa City, Iowa, USA. These antibodies have similar ability to recognize the respective recombinant SUMO proteins in immunoblotting (Fig. 1a) . We cultivated the hybridoma cells under conditions that allowed production of antibodies without contaminating bovine antibodies, immobilized the antibodies on protein G-agarose beads and optimized the conditions for immunoprecipitation of SUMOylated proteins. Asynchronously growing HeLa suspension cells were lysed in 1% SDS and 10 mM N-ethylmaleimide (NEM) to completely unfold and disrupt protein complexes and to inactivate SUMO isopeptidases. Sonication, heat denaturation in the presence of 50 mM dithiothreitol to disrupt disulfide and thioester bonds and ten-fold dilution to establish radioimmunoprecipitation assay (RIPA) buffer conditions were required before the addition of immobilized antibodies (Online Methods). At this and all subsequent steps, fresh NEM was added. Beads were harvested and washed, and bound proteins were eluted with Laemmli buffer after overnight incubation with cell lysate. With this protocol (Fig. 1b) , we were able to efficiently enrich endogenously SUMOylated proteins, as revealed by SDS-PAGE and subsequent immunoblotting with polyclonal antibodies to SUMO1 and SUMO2/3 (Fig. 1c) . As expected for unstressed mammalian cells 31 , the most prominent band in the SUMO1 immunoprecipitation is SUMOylated RanGAP1 (migrating at 90 kDa), and the most prominent band in the SUMO2 immunoprecipitation is free SUMO2/3 (migrating at 20 kDa). Although these findings showed that the monoclonal antibodies SUMO1 21C7 and SUMO2 8A2 are well suited for our aim, staining with colloidal Coomassie blue revealed no differences in the total protein content of the SUMO and control immunoprecipitations (Fig. 1d) . There was also no similarity between the overall protein pattern and the SUMO pattern (Fig. 1c compared to the S1 lane in Fig. 1d ). This indicates high unspecific binding, which not only causes severe background problems in MS-based analyses but also limits how much sample can be loaded.
Identification of epitope-spanning peptides
A well-known method to reduce contaminations in immunoprecipitations is selective elution of antigens from their antibodies with epitope-containing peptides, and it is frequently used in protocols involving antibodies to hemagglutinin or Flag tags [35] [36] [37] . As the epitopes recognized by the monoclonal antibodies SUMO1 21C7 and SUMO2 8A were unknown, we generated overlapping peptides covering the entire SUMO sequences and performed peptide-competition assays (Fig. 2a,b) . Once competing peptides were identified, we tested shorter variants to identify the minimal epitope-spanning peptides (data not shown). The peptides SUMO1 57-VPMNSLRFLFE-67 and SUMO2 57-IRFRFDGQPI-66 contain the epitope for the monoclonal antibodies SUMO1 21C7 and SUMO2 8A2, respectively.
Comparison of the epitope-spanning sequences in SUMO proteins from different species showed that the antibodies recognize SUMO in a range of model organisms. For SUMO1 21C7, the epitope is identical in humans, mice, chickens and Xenopus laevis (Fig. 2a) . Although zebrafish SUMO1 does not share full homology in this part of the sequence, additional peptide competition assays indicate that it is also recognized by the antibody (Supplementary Fig. 1 ), whereas C. elegans SUMO1 is too divergent. For SUMO2 8A2, the epitope is identical in humans, mice, chickens, X. laevis and zebrafish (Fig. 2b) ; D. melanogaster SUMO2, whose epitope-spanning region differs in one amino acid, is also recognized by the antibody, both in competition assays and in immunoblotting (Supplementary Fig. 1 ). 
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Establishing an efficient peptide elution protocol Having defined minimal epitope-spanning peptides, we next established efficient peptide elution conditions. A systematic analysis, including variations in pH, temperature, salt and detergent types, resulted in an elution protocol using RIPA buffer with 500 mM salt (Online Methods) for 30 min at 37 °C. With these conditions established, we repeated the immunoprecipitation from denatured HeLa lysates but used peptide elution rather than elution with Laemmli buffer (Fig. 3) . To test the specificity of the peptide elution, we employed three conditions for each immunoprecipitation: (i) anti-SUMO-antibody beads for elution with the corresponding epitopespanning peptides, (ii) anti-SUMO-antibody beads for elution with a control peptide and (iii) control beads for elution with the epitopespanning peptides. To evaluate the efficiency and specificity of the protocol, we analyzed samples by immunoblotting with polyclonal anti-SUMO antibodies. Both immunoprecipitation and peptide elution are efficient and specifically enrich SUMOylated proteins (Fig. 3a,b) . Of note, the small fraction of free SUMO2/3 that is visible in the eluate with control peptide is a consequence of the stringent elution conditions (buffer and elevated temperature) needed for efficient elution from the beads.
To test whether inclusion of the peptideelution step solves the problem of nonspecific contaminants in the SUMO immunoprecipitations, we performed large-scale experiments with HeLa cells, followed by peptide elution, trichloroacetic acid precipitation, SDS-PAGE and colloidal Coomassie staining (Fig. 3c) . Indeed, in contrast to the SDS elution (Fig. 1d) , the colloidal Coomassie staining after peptide elution resembles the signals in SUMO immunoblotting. In the SUMO1 immunoprecipitation, SUMO1-RanGAP1 was clearly visible as the most prominent band, and a high-molecular-weight smear could be detected in the whole lane. As revealed by densitometry, the intensity of the high-molecular-weight smear was nearly twice that of the control eluate, which indicated that a substantial proportion of the precipitated proteins was specific for the SUMO1 immunoprecipitation. In the SUMO2 immunoprecipitation, free SUMO2 was the strongest band, and a higher-molecular-weight smear of the conjugates was visible as well. To obtain further evidence that the Coomassie signal observed upon SUMO2 immunoprecipitations at least reflects most, if not all, SUMOylated proteins, we also compared SUMO2 immunoprecipitations from unstressed HeLa suspension cells to those subjected to heat shock (Fig. 3d) . As expected, free SUMO2/3 decreased, and the signal intensity in the highermolecular-weight range increased. In conclusion, the amount of unspecific proteins could be substantially reduced in the SUMO immunoprecipitation protocol that includes peptide elution. Epitope-spanning peptide for SUMO1 21C7 
Applying the protocol to a new monoclonal anti-SUMO1 antibody One remaining limitation of our protocol is that the monoclonal antibodies do not work with all species and may recognize some proteins that are not SUMOylated, owing to shared epitopes. To expand the list of useful anti-SUMO antibodies, we developed a new monoclonal antibody that was raised against a C-terminal peptide of SUMO1 (SUMO1 76-86 ; Online Methods). We mapped the minimal epitope-spanning peptide to SUMO1 76-TPKELGMEEED-86, which is identical in humans, mice, chickens and X. laevis (Fig. 4a) . To test whether our immunoprecipitation and peptide elution protocol permits exchange of the antibody without further need for optimization, we repeated the experiment shown in Figure 3a with SUMO1 76-86 . Indeed, the protocol works efficiently, as judged by the strong depletion of SUMO1 species in the flow through and the large recovery after peptide elution (Fig. 4b) .
Thus, anti-SUMO1 76-86 is an effective new monoclonal antibody, and our protocol works well with different monoclonal antibodies.
Comparison of the endogenous SUMOylated proteome
One key advantage of our method compared to those of previous studies is that the same cell extract is used as starting material for the enrichment of proteins modified by SUMO1 and SUMO2/3. As long as both immunoprecipitations lead to detectable depletion of SUMOylated proteins from the extract (Fig. 3) , the relative distribution of candidates enriched by SUMO1 and SUMO2/3 immunoprecipitations can be compared by using protein intensity values calculated by MaxQuant.
We thus decided to compare the endogenous SUMO1-and SUMO2/3-target proteome of asynchronously growing HeLa suspension cells. For this, we performed two independent large-scale immunoprecipitations and analyzed enriched proteins by MS after tryptic digest. More than 1,000 proteins could be identified in the SUMO immunoprecipitations, some of which might obviously be unspecific. We thus applied highly stringent selection criteria in the data analysis (Online Methods). Depending on whether we allowed up to 10% or 25% of background signal in the control immunoprecipitation, this led to a total of 232 or 584 different candidate proteins (Supplementary Table 1) .
For follow-up experiments, we focused on the more stringent list of 232 candidates. Graphical representation of relative intensity values revealed notable differences between the two SUMO immunoprecipitations (Fig. 5a) Anti-RanGAP1 
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anti-SUMO1 and the anti-SUMO2/3 antibodies compared to the control, 40% of all candidates showed enrichment in the SUMO1 immunoprecipitation, and 10% were found predominantly in the SUMO2/3 immunoprecipitation (>80% of total SUMO signal). Signal-intensity values for a selection of proteins are depicted in Table 1 . For example, the well-known SUMO1 target RanGAP1 was found predominantly in the SUMO1 immunoprecipitation 33, 38 . The SUMO targets PML 39 To verify this paralog selectivity as determined by MS, we analyzed samples from large-scale immunoprecipitations (Fig. 5b) in immunoblotting experiments. Both SUMOylation as well as paralog selectivity of all known SUMO targets could be confirmed (Fig. 5c) . We also verified the SUMOylation of two newly identified targets, the splicing factor RBM25 (ref. 42 ) and the zinc-finger protein WIZ 43 (Fig. 5c) . Whereas WIZ also showed the expected paralog preference, the signals obtained for RBM25 in immunoblotting (reproducible preference for SUMO1; faint signal for SUMO2 in long exposures) deviated from those obtained by MS (similar intensities for SUMO1 and SUMO2/3). A possible explanation of this apparent discrepancy is the difference between both methods: whereas values obtained from the MS analysis reflect the sum of peptides in the whole gel, in immunoblotting, faint high-molecular-weight bands that would derive from SUMO2/3 chains may be below the detection level.
From that, we conclude that our immunoprecipitation and peptide elution protocol is a reliable tool to enrich and verify endogenously SUMOylated proteins, including those that were previously very difficult to detect, such as SUMOylated Ubc9 (ref. 41 ).
Enrichment of SUMOylated proteins from liver tissue
To cover a broad range of applications, we tested whether our protocol can enrich SUMOylated proteins from a complex tissue like mouse liver. Although most steps could be applied from the immunoprecipitation protocol for HeLa cells, an additional step for the preabsorption of antibodies (which are intrinsically present in the lysates of blood vessel-containing organs) had to be included (Fig. 6a) . Successful SUMO1 and SUMO2 immunoprecipitations were obtained from mouse liver extracts (Fig. 6b) . Similar to the results obtained for HeLa cells (Fig. 3a,b) , depletion was observed in the flow-through sample after immunoprecipitation with anti-SUMO but not control antibodies and strong enrichment of the SUMO signal in the eluate with the epitope-spanning (epi) but not the control (con) peptide. We next tested whether our protocol is applicable to verification of specific SUMO targets in mouse liver and were able to confirm endogenous SUMOylation of the known targets RanGAP1 (refs. 33,38), Trim28 (ref. 40) and Prox1 (ref. 44 ) by immunoblotting (Fig. 6c) . These experiments clearly demonstrate that our protocol is universally applicable to study endogenous SUMOylation.
DISCUSSION
Although SUMOylation is one of the major regulatory protein modifications, tools for the analysis of endogenous SUMOylation are still scarce. Here, we provide a method that allows efficient enrichment of endogenously mono-or poly-SUMOylated proteins, both from cell lines and complex organ tissue. With the currently available antibodies, the protocol should be applicable to all vertebrates (including mammals, fish, birds and amphibians) and also to Drosophila (Fig. 2 and  Supplementary Fig. 1) , and it can probably be expanded to any other biological material as soon as the respective monoclonal SUMO antibodies and corresponding epitope-spanning peptides become available.
Analysis of the SUMO proteome
Here, we provide what is, to our knowledge, the first endogenous SUMO1-and SUMO2/3-modified proteome candidate lists from asynchronously growing HeLa suspension cells, which includes 584 different proteins (Supplementary Table 1) . How do these putative targets compare to verified SUMO targets and candidates from other proteomic approaches? First, at least 30 proteins (13%) on our highstringency list (232 proteins with less than 10% signal in the control Table 2 ). This indicates that many proteins subject to chain formation of SUMO2/3 upon heat shock are already monoSUMOylated in the absence of stress. Taken together, our own validation (Fig. 5 ) and the comparison with different studies confirm the credibility of our list of 584 endogenous SUMO target candidates and the overall quality of the method.
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Paralog-specific SUMOylation
As described above, our data indicate that most SUMO targets in asynchronously growing HeLa suspension cells are modified with both SUMO1 and SUMO2/3, however with highly variable relative ratios (Fig. 5a) . Of all SUMO targets, 40% seem preferentially modified with SUMO1 and only 10% with SUMO2/3. In light of a previous study with stable HeLa cell lines expressing His-SUMO 17 , our finding may appear surprising. The study found 55 SUMO targets, with 25 being preferentially modified with SUMO1, 19 with SUMO2 and only 9 (16%) similarly modified with both paralogs. A key difference from our study, however, is that the previous study compared two different stable cell lines overexpressing His-tagged SUMO1 and SUMO2. Because endogenous SUMO was still present, both the relative levels of SUMO1 versus SUMO2/3 and the ratio between endogenous and tagged SUMO paralogs was different. Although our protocol requires two different monoclonal antibodies (which could possibly give rise to different contaminants that would be identified as paralog specific), it has the strong advantage that a single cell extract can be used for both immunoprecipitations. This allows for direct comparison by MS, immunoprecipitation and immunoblotting, as long as SUMO1 and SUMO2/3 targets are enriched with comparable efficiency. Assuming that many proteins have the potential to be SUMOylated by both SUMO variants, factors that contribute to paralog-specific modification are the relative abundance of SUMO1 and SUMO2/3 proteins and relative isopeptidase activities. In line with this idea, SUMO2/3 can compensate for loss of SUMO1 in a knockout mouse model 45 . Of particular interest, however, are those proteins that show a striking preference for SUMO1 or SUMO2/3. Three mechanisms concerning their paralog preference have been described. It might originate from an E3 ligase, as is the case for the small E3 ligase fragment of RanBP2 that carries a SIM to facilitate recruitment of SUMO1-loaded Ubc9 (refs. 46,47) . Similarly, the preference may be caused by a SIM in the target (SIM-dependent SUMOylation), as has been suggested for the DNA helicase BLM 48 and the ubiquitin-specific protease Usp25 (ref. 49) , both of which are preferentially modified with SUMO2/3. Finally, a protein may be modified with SUMO1 and with SUMO2/3, but selective protection of one SUMOylated species from SUMO isopeptidases may allow this form to accumulate. Such a mechanism explains the marked preference of RanGAP1 for SUMO1, which can form an isopeptidase-resistant complex with RanBP2 and Ubc9 only when modified with SUMO1 but not when modified with SUMO2/3 (refs. 50, 51) . The list presented here of proteins that show a preference for SUMO1 or SUMO2/3 offer an ideal resource for investigating additional mechanisms underlying paralog specificity.
Outlook
We described a universally applicable and affordable method to identify and investigate individual endogenously SUMOylated proteins as well as the endogenous SUMO proteome. It could be easily combined with second purification steps, for example to study proteins carrying two modifications simultaneously, and is suitable for quantitative approaches such as MS after stable isotope labeling by amino acids in cell culture (SILAC) labeling. Our method will thus greatly facilitate the analysis of one of the most common post-translational modifications.
METHODS
Methods and any associated references are available in the online version of the paper. 
